Podcasts about AstraZeneca

Play Episode Listen Later Aug 14, 2025 37:32

"Burnout and trauma are not mental illnesses. They live in your physiology. They live in your biology. They live very specifically in your nervous system,” Dr. Rola Hallam says with a conviction rooted in her own successful journey to overcome the effects of chronic stress she accumulated during many years on the frontlines of humanitarian crises in Syria and other conflict zones. Out of concern for the multitudes of health professionals who, like herself, spend years carrying the weight of their traumatic experiences without seeking help, or who pursue ineffective remedies for relieving it, Dr. Rola -- as she's known – has shifted her focus to being a trauma and burnout coach. Among her offerings is Beyond Burnout, a twelve-week program that includes multimedia content as well as live coaching and teaching about developing nervous system awareness and regulation. “Most wellness initiatives fail because they're not rewiring the nervous system to come out of survival mode and back into what is called the ventral-vagal state, which is our state of social connection and of healing and repair.” She also stresses that healing is not an individual pursuit, especially for providers who work in a relational field, and teaches about the benefits of borrowing from a colleagues' state of calm and offering them the same. Don't miss this insightful and giving conversation with host Lindsey Smith that covers Dr. Rola's wrenching experiences providing care in desperate conditions, the critically important distinction between empathy and compassion, and how empowering frontline workers to heal their trauma can uplift individuals and empower entire communities. Mentioned in this episode:Dr. Rola CoachingBeyond Burnout AssessmentCanDo - Humanitarian Aid If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

covid-19 founders ai interview technology coronavirus pandemic doctors podcasts trauma burnout viruses testing vaccines addressing life coach nurses root cdc fda syria public health psychedelics epidemics medicare machine learning public policy moderna lsd medicaid johns hopkins university mark cuban astrazeneca big pharma health insurance telehealth mdma edtech healthcare system psilocybin delta variant primary care pharmaceuticals wearables digital health continuing education home care medical education rare diseases rola gene editing healthcare providers medicare advantage online education nervous system regulation health care reform chelsea clinton government policy elsevier health professions osmosis value based care polyvagal flatten the curve nursing school hallam war zones eric topol learning sciences flipped classroom nursing education remote monitoring syrian war decision support johnson & johnson education innovation spaced repetition centers for disease control vivian lee rare disorders lindsey smith virus outbreak dental education hospital systems healthcare entrepreneurs shiv gaglani medical degrees frontline providers

Season 3 - Ep.22: Oral anticoagulation in afib - Smartwatch, heart rate and ECG

Play Episode Listen Later Aug 14, 2025 22:04

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Season 3 - Ep.22: Extended interview on on smartwatch, heart rate and ECG

Dear Cancer, I'm Beautiful

Play Episode Listen Later Aug 14, 2025 13:34

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Beyond the BRCA Gene: A Story of Risk Awareness and Breast Cancer Prevention, with Krista Brown, Oncology Nurse Navigator

Play Episode Listen Later Aug 13, 2025 43:48

In this compelling episode, host Melissa Berry continues the series "Decoding Destiny: Navigating Breast Cancer with Genetic Insight" with a heartfelt conversation with Krista Brown, also known on Instagram as the Cancer Prevention Coach. Krista, an oncology nurse navigator and breast cancer survivor, shares her journey of living with an ATM gene mutation and the empowering role of genetic testing in her life. Together, they explore the importance of education, nutrition, and self-advocacy in managing hereditary cancer risks. Tune in to discover how Krista's personal experiences have shaped her mission to fill gaps in patient education and support others on their cancer prevention journeys. Special thanks to AstraZeneca for making this episode possible.

risk cancer nurses breast cancer astrazeneca atm oncology genetic testing brca breast cancer prevention nurse navigator

Interventions to Reduce Financial Toxicity in Breast Cancer

ASCO eLearning Weekly Podcasts

Play Episode Listen Later Aug 11, 2025 27:14

Dr. Hope Rugo and Dr. Kamaria Lee discuss the prevalence of financial toxicity in cancer care in the United States and globally, focusing on breast cancer, and highlight key interventions to mitigate financial hardship. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm your host, Dr. Hope Rugo. I'm the director of the Women's Cancer Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. Rising healthcare costs are causing financial distress for patients and their families across the globe. Patients with cancer report financial toxicity as a major impediment to their quality of life, and its association with worse outcomes is well documented. Today, we'll be discussing how patients with breast cancer are uniquely at risk for financial toxicity. Joining me for this discussion is Dr. Kamaria Lee, a fourth-year radiation oncology resident and health equity researcher at MD Anderson Cancer Center and a co-author of the recently published article titled, "Financial Toxicity in Breast Cancer: Why Does It Matter, Who Is at Risk, and How Do We Intervene?" Our full disclosures are available in the transcript of this episode. Dr. Lee, it's great to have you on this podcast. Dr. Kamaria Lee: Hey, Dr. Rugo. Thank you so much for having me. I'm excited to be here today. I also would like to recognize my co-authors, Dr. Alexandru Eniu, Dr. Christopher Booth, Molly MacDonald, and Dr. Fumiko Chino, who worked on this book chapter with me and did a fantastic presentation on the topic at ASCO this past year. Dr. Hope Rugo: Thanks very much. We'll now just jump into the questions. We know that rising medical costs contribute to a growing financial burden on patients, which has [GC1] [JG2] been documented to contribute to lower quality-of-life, compromised clinical care, and worse health outcomes. How are patients with breast cancer uniquely at risk for financial toxicity? How does the problem vary within the breast cancer population in terms of age, racial and ethnic groups, and those who have metastatic disease? Dr. Kamaria Lee: Breast cancer patients are uniquely at risk of financial toxicity for several reasons. Three key reasons are that breast cancer often requires multimodal treatment. So this means patients are receiving surgery, many receive systemic therapies, including hormonal therapies, as well as radiation. And so this requires care coordination and multiple visits that can increase costs. Secondly, another key reason that patients with breast cancer are uniquely at risk for financial toxicity is that there's often a long survivorship period that includes long-term care for toxicities and continued follow-ups, and patients might also be involved in activities regarding advocacy, but also physical therapy and mental health appointments during their prolonged survivorship, which can also add costs. And a third key reason that patients with breast cancer are uniquely at risk for financial toxicity is that the patient population is primarily women. And we know that women are more likely to have increased caregiver responsibilities while also potentially working and managing their treatments, and so this is another contributor. Within the breast cancer population, those who are younger and those who are from marginalized racial/ethnic groups and those with metastatic disease have been shown to be at an increased risk. Those who are younger may be more likely to need childcare during treatment if they have kids, or they're more likely to be employed and not yet retired, which can be disrupted while receiving treatment. And those who are racial/ethnic minorities may have increased financial toxicity due to reasons that exist even after controlling for socioeconomic factors. And some of these reasons have been shown to be increased risk of job or income loss or transportation barriers during treatment. And lastly, for those with metastatic breast cancer, there can be ongoing financial distress due to the long-term care that is needed for treatment, and this can include parking, transportation, and medications while managing their metastatic disease. Dr. Hope Rugo: I think it is really important to understand these issues as you just outlined. There has been a lot of focus on financial toxicity research in recent years, and that has led to novel approaches in screening for financial hardship. Can you tell us about the new screening tools and interventions and how you can easily apply that to clinical practice, keeping in mind that people aren't at MD Anderson with a bunch of support and information on this but are in clinical practice and seeing many, many patients a day with lots of different cancers? Dr. Kamaria Lee: You're exactly right that there is incredible nuance needed in understanding how to best screen for financial hardship in different types of practices. There are multiple financial toxicity tools. The most commonly used tool is the Comprehensive Score for Financial Toxicity, also known as the COST tool. In its full form, it's an 11-item survey. There's also a summary question as well. And these questions look at objective and subjective financial burden, and it uses a five-point Likert scale. For example, one question on the full form is, "I know that I have enough money in savings, retirement, or assets to cover the cost of my treatment," and then patients are able to respond "not at all" to "very much" with a threshold score for financial toxicity risk. Of course, as you noted, one critique of having an 11-item survey is that there's limited time in patient encounters with their providers. And so recently, Thom et al validated an abbreviated two-question version of the COST tool. This validation was done in an urban comprehensive cancer center, and it was found to have a high predictive value to the full measure. We note which two questions are specifically pulled from the full measure within the book chapter. And this is one way that it can be easier for clinicians who are in a busier setting to still screen for financial toxicity with fewer questions. I also do recommend that clinicians who know their clinic's workflow the best, work with their team of nurses, financial navigators, and others to best integrate the tool into their workflow. For some, this may mean sending the two-item survey as a portal message so that patients can answer it before consults. Other times, it could mean having it on the tablet that can be done in the clinic waiting room. And so there are different ways that screening can be done, even in a busy setting, and acknowledging that different practices have different amounts of resources and time. Dr. Hope Rugo: And where would people access that easily? I recognize that that information is in your chapter, or your article that's on PubMed that will be linked to this podcast, but it is nice to just know where people could easily access that online. Dr. Kamaria Lee: Yes, and so you should be able to Google ‘the COST measure', and then there is a website that also has the forms as well. So it's also beyond the book chapter, Googling ‘the COST measure', and then online they would be able to find access to the form. Dr. Hope Rugo: And how often would you do that screening? Dr. Kamaria Lee: So, I think it's definitely important that we are as proactive as possible. And so initially, I recommend that the screening happens at the time of diagnosis, and so if it's done through the portal, it can be sent before the initial consult, or again, however, is best in the workflow. So at the time of diagnosis and then at regular intervals, so throughout the treatment process, but then also into the follow-up period as well to best understand if there's still a financial burden even after the treatments have been completed. Dr. Hope Rugo: I wonder if in the metastatic setting, you could do it at the change of treatment, you know, a month after somebody's changed treatment, because people may not be as aware of the financial constraints when they first get prescribed a drug. It's more when you hear back from how much it's going to cost. And leading into that, I think it's, what do you do with this? So, you know, this cost conversation is really important. You're going to be talking to the patient about the cost considerations when you, for example, see that there are financial issues, you're prescribing treatments. How do we implement impactful structured cost conversations with our breast cancer patients, help identify financial issues, and intervene? How do we intervene? I mean, as physicians often we aren't really all that aware, or providers, of how to address the cost. Dr. Kamaria Lee: Yes, I agree fully that another key time when to screen for financial toxicity is at that transition between treatments to best understand where they're at based off of what they've received previously for care, and then to anticipate needs when changing regimens, such as like you said in the metastatic setting. As we're collecting this information, you're right, we screen, we get this information, and what do we do? I do agree that there is a lack of knowledge among us clinicians of how do we manage this information. What is insurance? How do we manage insurance and help patients with insurance concerns? How do we help them navigate out-of-pocket costs or even the indirect costs of transportation? Those are a lot of things that are not covered in-depth in traditional medical training. And so it can be overwhelming for a lot of clinicians, not only due to time limitations in clinic, but also just having those conversations within their visit. And so what I would say, a key thing to note, is that this is another area for multidisciplinary care. So just as we're treating patients in a multidisciplinary way within oncology as we work with our medical oncology, surgical colleagues across the board, it's knowing that this is another area for multidisciplinary care. So the team members include all of the different oncologists, but it also includes team members such as financial counselors and navigators and social workers and even understanding nonprofit partners who we have who have money that can be set aside to help reduce costs for certain different aspects of treatment. Another thing I will note is that most patients with breast cancer often say they do want to have these conversations still with their clinicians. So they do still see a clinician as someone that can weigh in on the costs of their treatment or can weigh in on this other aspect of their care, even if it's not the actual medication or the radiation. And so patients do desire to hear from their clinicians about this topic, and so I think another way to make it feel less overwhelming for clinicians like ourselves is to know that even small conversations are helpful and then being knowledgeable about within your institution or, like I said, outside of it with nonprofits, being aware of who can I refer this patient to for continued follow-up and for more detailed information and resources. Dr. Hope Rugo: Are those the successful interventions? It's really referring to financial navigators? How do people identify? You know, in an academic center, we often will sort of punt this to social workers or our nurse navigators. What about in the community? What's a successful intervention example of mitigating financial toxicity? Dr. Kamaria Lee: I agree completely that the context at which people are practicing is important to note. So as you alluded to, in some bigger systems, we do have financial navigators and this has been seen to be successful in providing applications and assisting with applications for things such as pharmaceutical assistance, insurance applications, discount opportunities. Another successful intervention are financial toxicity tumor boards, which I acknowledge might not be able to exist everywhere. But where this is possible, multidisciplinary tumor boards that include both doctors and nurses and social workers and any other members of the care team have been able to effectively decrease patients' personal spending on care costs and decrease co-pays through having a dedicated time to discuss concerns as they arise or even proactively. Otherwise, I think in the community, there are other interventions in regards to understanding different aspects of government programs that might be available for patients that are not, you know, limited to an institution, but that are more nationally available, and then again, also having the nonprofit, you know, partnerships to see other resources that patients can have access to. And then I would also say that the indirect costs are a significant burden for many patients. So by that, I mean even parking costs, transportation, childcare. And so even though those aren't interventions necessarily with someone who is a financial navigator, I would recommend that even if it's a community practice, they discuss ways that they can help offset those indirect costs with patients with parking or if there are ways to help offset transportation costs or at least educate patients on other centers that may be closer to them or they can still receive wonderful care, and then also making sure that patients are able to even have appointments scheduled in ways that are easier for them financially. So even if someone's receiving care out in the community where there's not a financial navigator, as clinicians or our scheduling teams, sometimes there are options to make sure if a patient wants, visits are more so on one day than throughout the week or many hours apart that can really cause loss of income due to missed work. And so there are also kind of more nuanced interventions that can happen even without a financial navigation system in place. Dr. Hope Rugo: I think that those are really good points and it is interesting when you think about financial toxicity. I mean, we worry a lot when patients can't take the drugs because they can't afford them, but there are obviously many other non-treatment, direct treatment-related issues that come up like the parking, childcare, tolls, you know, having a working car, all those kinds of things, and the unexpected things like school is out or something like that that really play a big role where they don't have alternatives. And I think that if we think about just drug costs, I think those are a big issue in the global setting. And your article did address financial toxicity in the global setting. International financial toxicity rates range from 25% of patients with breast cancer in high-income countries to nearly 80% in low- and middle-income countries or LMICs. You had cited a recent meta-analysis of the global burnout from cancer, and that article found that over half of patients faced catastrophic health expenditures. And of course, I travel internationally and have a lot of colleagues who are working in oncology in many countries, and it is really often kind of shocking from our perspective to see what people can get coverage for and how much they have to pay out-of-pocket and how much that changes, that causes a lot of disparity in access to healthcare options, even those that improve survival. Can you comment on the global impact of this problem? Dr. Kamaria Lee: I am glad that you brought this up for discussion as well. Financial toxicity is something that is a significant global issue. As you mentioned, as high as 80% of patients with breast cancer in low- and middle-income countries have had significant financial toxicity. And it's particularly notable that even when looking at breast cancer compared to other malignancies around the world, the burden appears to be worse. This has been seen even in countries with free universal healthcare. One example is Sri Lanka, where they saw high financial toxicity for their patients with breast cancer, even with this free universal healthcare. But there were also those travel costs and just additional out-of-hospital tests that were not covered. Also, literature in low- and middle-income countries shows that patients might also be borrowing money from their social networks, so from their family and their friends, to help cover their treatment costs, and in some cases, people are making daily food compromises to help offset the cost of their care. So there is a really large burden of financial toxicity generally for cancer globally, but also specifically in breast cancer, it warrants specific discussion. In the meta-analysis that you mentioned, they identified key risk factors of financial toxicity globally that included people who had a larger family size, a lower income, a lack of insurance, longer disease duration, so again, the accumulation of visits and costs and co-pay over time, and those who had multiple treatments. And so in the global setting, there is this significant burden, but then I will also note that there is a lack of literature in low-income countries on financial toxicity. So where we suspect that there is a higher burden and where we need to better understand how it's distributed and what interventions can be applied, especially culturally specific interventions for each country and community, there's less research on this topic. So there is definitely an increased need for research in financial toxicity, particularly in the global setting. Dr. Hope Rugo: Yes, and I think that goes on to how we hope that financial toxicity researchers will have approaches to large-scale multi-institutional interventions to improve financial toxicity. I think this is an enormous challenge, but one of the SWOG organizations has done some great work in this area, and a randomized trial addressing cancer-related financial hardship through the delivery of a proactive financial navigation intervention is one area that SWOG has focused on, which I think is really interesting. Of course, that's going to be US-based, which is how we might find our best paths starting. Do you think that's a good path forward, maybe that being able to provide something like that across institutions that are independent of being a cancer only academic center, or more general academic center, or a community practice? You know, is finding ways to help patients with breast cancer and their families understand and better manage financial aspects of cancer care on a national basis the next approach? Dr. Kamaria Lee: Yes, I agree that that is a good approach, and I think the proactive component is also key. We know that patients that are coming to us with any cancer, but including breast cancer, some of them have already experienced a financial burden or have recently had a job loss before even coming to us and having the added distress of our direct costs and our indirect costs. So I think being proactive when they come to us in regards to the additional burden that their cancer treatments may cause is key to try to get ahead of things as much as we can, knowing that even before they've seen us, there might be many financial concerns that they've been navigating. I think at the national level, that allows us to try to understand things at what might be a higher level of evidence and make sure that we're able to address this for a diverse cohort of patients. I know that sometimes the enrollment can be challenging at the national level when looking at financial toxicity, as then we're involving many different types of financial navigation partners and programs, and so that can maybe make it more complex to understand the best approaches, but I think that it can be done and can really bring our understanding of important financial toxicity interventions to the next level. And then the benefit to families with the proactive component is just allowing them to feel more informed, which can help decrease anticipation, anxiety related to anticipation, and allow them to help plan things moving forward for themselves and for the whole family. Dr. Hope Rugo: Those are really good points and I wonder, I was just thinking as you were talking, that having some kind of a process where you could attach to the electronic health record, you could click on the financial toxicity survey questions that somebody filled out, and then there would be a drop-down menu for interventions or connecting you to people within your clinic or even more broadly that would be potential approaches to manage that toxicity issue so that it doesn't impact care, you know, that people aren't going to decide not to take their medication or not to come in or not to get their labs because of the cost or the transportation or the home care issues that often are a big problem, even parking, as you pointed out, at the cancer center. And actually, we had a philanthropic donor when I was at UCSF who donated a large sum of money for patient assistance, and it was interesting to then have these sequential meetings with all the stakeholders to try and decide how you would use that money. You need a big program, you need to have a way of assessing the things you can intervene with, which is really tough. In that general vein, you know, what are the governmental, institutional, and provider-level actions that are required to help clinicians do our best to do no financial harm, given the fact that we're prescribing really expensive drugs that require a lot of visits when caring for our patients with breast cancer in the curative and in the metastatic setting? Dr. Kamaria Lee: At the governmental level, there are patient assistant programs that do exist, and I think that those can continue and can become more robust. But I also think one element of those is oftentimes the programs that we have at the government level or even institutional levels might have a lot of paperwork or be harder for people with lower literacy levels to complete. And so I think the government can really try to make sure that the paperwork that is given, within reason, with all the information they need, but that the paperwork can be minimized and that there can be clear instructions, as well as increased health insurance options and, you know, medical debt forgiveness as more broad just overall interventions that are needed. I think additionally, institutions that have clinical trials can help ensure that enrollment can be at geographically diverse locations. Some trials do reimburse for travel costs, of course, but sometimes then patients need the reimbursement sooner than it comes. And so I think there's also those considerations of more so upfront funds for patients involved in clinical trials if they're going to have to travel far to be enrolled in that type of care or trying to, again, make clinical trials more available at diverse locations. I would also say that it's important that those who design clinical trials use what is known as the “Common Sense Oncology” approach of making sure that they're designed in minimizing the use of outcomes that might have a smaller clinical benefit but may have a high financial toxicity. And that also goes to what providers can do, of understanding what's most important to a particular patient in front of them, what outcomes and what benefit, or you know, how many additional months of progression-free survival or things like that might be important to a particular patient and then also educating them and discussing what the associated financial burden is just so that they have the full picture as they make an informed decision. Dr. Hope Rugo: As much as we know. I mean, I think that that's one of the big challenges is that as we prescribe these expensive drugs and often require multiple visits, even, you know, really outside of the clinical trial setting, trying to balance the benefit versus the financial toxicity can be a huge challenge. And that's a big area, I think, that we still need help with, you know. As we have more drugs approved in the early-stage setting and treatments that could be expensive, oral medications, for example, in our Medicare population where the share of cost may be substantial upfront, you know, with an upfront cost, how do we balance the benefits versus the risk? And I think you make an important point that discussing this individually with patients after we found out what the cost is. I think warning patients about the potential for large out-of-pocket cost and asking them to contact us when they know is one way around this. You know, patients feeling like they're sort of out there with a prescription, a recommendation from their doctor, they're scared of their cancer, and they have this huge share of cost that we didn't know about. That's one challenge, and I don't know if there's any suggestions you have about how one should approach that communication with the patient. Dr. Kamaria Lee: Yes, I think part of it is truly looking at each patient as an individual and asking how much they want to know, right? So we all know that patients, some who want more information, some want less, and so I think one way to approach that is asking them about how much information do they want to know, what is most helpful to them. And then also, knowing that if you're in a well-resourced setting that does have the social workers and financial navigators, also making sure it's integrated in the multidisciplinary setting and so that they know who they can go to for what, but also know that as a clinician, you're always happy for them to bring up their concerns and that if it's something that you're not aware of, that you will connect them to the correct multidisciplinary team members who can accurately provide that additional information. Dr. Hope Rugo: Do you have any other additional comments that you'd like to mention that we haven't covered? I think the idea of a financial toxicity screen with two questions that could be implemented at change of therapy or just periodically throughout the course of treatment would be a really great thing, but I think we do need as much information on potential interventions as possible because that's really what challenges people. It's like finding out information that you can't handle. Your article provides a lot of strategies there, which I think are great and can be discussed on a practice and institutional level and applied. Dr. Kamaria Lee: Yeah, I would just like to thank you for the opportunity to discuss such an important topic within oncology and specifically for our patients with breast cancer. I agree that it can feel overwhelming, both for clinicians and patients, to navigate this topic that many of us are not as familiar with, but I would just say that the area of financial toxicity is continuing to evolve as we gather more information on most successful interventions and that our patients can often inform us on, you know, what interventions are most needed as we see them. And so you can have your thinking about it as you see individual patients of, "This person mentioned this could be more useful to them." And so I think also learning from our patients in this space that can seem overwhelming and that maybe we weren't all trained on in medical school to best understand how to approach it and how to give our patients the best care, not just medically, but also financially. Dr. Hope Rugo: Thank you, Dr. Lee, for sharing your insights with us today. Our listeners will find a link, as I mentioned earlier, to the Ed Book article we discussed today in the transcript of this episode. I think it's very useful, a useful resource, and not just for providers, but for clinic staff overall. I think this can be of great value and help open the discussion as well. Dr. Kamaria Lee: Thank you so much, Dr. Rugo. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at Education Sessions from ASCO meetings and our deep dives into new approaches that are shaping modern oncology. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Hope Rugo @hope.rugo Dr. Kamaria Lee @ lee_kamaria Follow ASCO on social media:      @ASCO on X (formerly Twitter)      ASCO on Bluesky     ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Kamaria Lee: No relationships to disclose

A Mother's Legacy Inspires A Passion for Equity in Healthcare: Dr. Uche Blackstock, Founder and CEO of Advancing Health Equity

ceo discovery careers astrazeneca biotech cso brenner recursion

Play Episode Listen Later Aug 7, 2025 24:42

“Seeing that you can get through the most difficult times in life, succeed, and then also return to your community and work in service to your community was a lesson that has stuck with me,” says Dr. Uche Blackstock, the Founder and CEO of Advancing Health Equity and our guest on this inspiring episode of Raise the Line with Osmosis from Elsevier. It was a lesson the Harvard-trained physician learned from her own mother – also a Harvard trained physician – who overcame poverty, sexism and racial bias to forge an inspiring path. In her bestselling book, Legacy: A Black Physician Reckons with Racism in Medicine, Dr. Blackstock weaves her mother's remarkable story with her own and argues for systemic change in a healthcare system riddled with racially-biased practices and policies that impact patient outcomes. As she explains to host Lindsey Smith, Advancing Health Equity's work to drive measurable and sustainable change is focused on embedding equity as a core value in the leadership, strategy, and organizational practice of health systems. “We exist to challenge inequities, empower underrepresented communities, and help build a healthcare system where everyone can thrive.” Don't miss a thought-provoking conversation with a nationally respected voice that also addresses race correction factors that impact the care of Black patients, and the work required of health institutions to build trust in effected communities.Mentioned in this episode:Advancing Health EquityLegacy: A Black Physician Reckons with Racism in Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

covid-19 ceo founders black ai interview mother technology coronavirus pandemic passion doctors podcasts medicine healthcare racism viruses harvard testing vaccines raise nurses cdc fda public health psychedelics pfizer epidemics medicare machine learning omicron public policy moderna lsd medicaid johns hopkins university mark cuban astrazeneca big pharma inspires health insurance telehealth mdma edtech healthcare system psilocybin delta variant primary care pharmaceuticals wearables digital health continuing education home care medical education rare diseases gene editing medicare advantage online education health care reform chelsea clinton government policy drug development elsevier health professions osmosis value based care flatten the curve nursing school eric topol learning sciences blackstock flipped classroom nursing education remote monitoring drug costs pharmacy benefit managers decision support johnson & johnson education innovation spaced repetition centers for disease control vivian lee rare disorders lindsey smith advancing health equity virus outbreak healthcare equity dental education hospital systems uche blackstock shiv gaglani healthcare entrepreneurs medical degrees frontline providers

Legal News for Thurs 8/7 - SEC Gag Rule Endures, Stanford Student Paper Free Speech Suit, Revived Drug Discounts and a Class Action Against Pepsi

Minimum Competence

Play Episode Listen Later Aug 7, 2025 7:20

This Day in Legal History: Gulf of Tonkin ResolutionOn August 7, 1964, the U.S. Congress passed the Gulf of Tonkin Resolution, dramatically reshaping the legal landscape of American military engagement. Prompted by reports—later disputed—of North Vietnamese attacks on the USS Maddox in the Gulf of Tonkin, the resolution granted President Lyndon B. Johnson broad authority to use military force in Southeast Asia without a formal declaration of war. It passed nearly unanimously, with only two dissenting votes in the Senate, reflecting the tense Cold War atmosphere and congressional trust in the executive branch.Legally, the resolution functioned as an open-ended authorization for the president to escalate military operations in Vietnam. Within months, it led to the deployment of hundreds of thousands of U.S. troops. Critics would later argue that it allowed the executive to bypass Congress's constitutional war-making powers, effectively green-lighting a years-long conflict based on contested facts.As the war dragged on and public opinion turned, the resolution became a focal point for debates over separation of powers, congressional oversight, and executive overreach. In 1971, amid growing backlash, Congress repealed the resolution, but its legacy endured. It served as a legal and historical precedent for future authorizations of force, including those passed after 9/11.A federal appeals court has upheld the SEC's long-standing “gag rule,” which prevents defendants who settle civil enforcement cases from publicly denying the agency's allegations. The 9th Circuit Court of Appeals ruled 3-0 that the rule is not unconstitutional on its face but left room for future challenges depending on how it's applied. The policy, in place since 1972, requires settling parties to at least refrain from admitting or denying wrongdoing. The court emphasized that defendants remain free to reject settlements if they wish to speak out.Twelve petitioners, including former Xerox CFO Barry Romeril and the New Civil Liberties Alliance (NCLA), challenged the SEC's January 2024 decision not to revise the rule. Romeril had previously brought a similar challenge to the Supreme Court with support from Elon Musk, but the Court declined to hear it. Writing for the panel, Judge Daniel Bress noted that removing the gag could reduce the SEC's ability to settle cases efficiently and that speech restrictions are voluntary components of settlement agreements.The NCLA criticized the decision, arguing it effectively sanctions government-imposed silence and announced plans to pursue further appeals. SEC Commissioner Hester Peirce also dissented from the agency's refusal to revisit the rule, arguing that it hinders public accountability by suppressing potential criticism. The SEC declined to comment on the ruling, which came in the case Powell et al v. SEC.US appeals court upholds SEC 'gag rule' over free speech objections | ReutersThe Stanford Daily, Stanford University's student newspaper, has filed a lawsuit against the Trump administration, accusing it of violating the free speech rights of foreign students. The suit, filed in federal court in California, alleges that threats of arrest, detention, or deportation have created a climate of fear among international students, discouraging them from writing about sensitive political issues—particularly the Israeli-Palestinian conflict. Two unnamed students joined the paper in the lawsuit, which names Secretary of State Marco Rubio and Secretary of Homeland Security Kristi Noem as defendants.According to the plaintiffs, the administration has labeled pro-Palestinian viewpoints as antisemitic or extremist and attempted to deport students expressing such views, framing them as threats to U.S. foreign policy. In some instances, students have been detained without charges, though judges have later ordered their release. The lawsuit contends that these actions have led to widespread self-censorship among international students, chilling constitutionally protected speech in areas such as protests, slogans, and commentary on U.S. and Israeli policy.The Stanford Daily is seeking a court ruling affirming that the First Amendment protects non-citizens from government retaliation based on their speech. The university clarified it is not involved in the suit, as the newspaper operates independently. Attorney Conor Fitzpatrick, representing the paper, called the government's actions antithetical to American values of free expression.Stanford student newspaper sues Trump administration for alleged free speech violations | ReutersA U.S. appeals court has reinstated a lawsuit accusing major drugmakers Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to limit drug discounts provided under the federal 340B program. The 2nd Circuit Court of Appeals reversed a lower court's dismissal, allowing two health clinics—Mosaic Health and Central Virginia Health Services—to proceed with their proposed class action. These clinics claim the companies colluded in 2020 to restrict discounts on diabetes medications, harming safety-net providers and the low-income patients they serve.The court found that because the four companies control much of the diabetes drug market, coordination to limit discounts could be feasible. Judge Myrna Pérez, writing for the panel, noted the allegations were plausible enough to move forward. The drugmakers have denied wrongdoing and argue their policies were developed independently to address alleged fraud in the 340B program. Sanofi and Novo Nordisk said they are reviewing the decision, while Lilly criticized the ruling and defended its practices as legal.The clinics say the drugmakers earned billions in extra profits through these policies, which allegedly undercut essential savings for providers. The case underscores the broader tension between pharmaceutical companies and healthcare providers over the administration of the 340B program, which requires drugmakers to offer discounts in exchange for access to federal healthcare funds.US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies | ReutersPepsiCo is facing a proposed class action lawsuit alleging it engaged in illegal price discrimination by giving more favorable pricing and discount terms to large retailers like Walmart while denying the same deals to smaller businesses. Filed in federal court in Manhattan by an Italian restaurant operator, the lawsuit claims this practice violates the Robinson-Patman Act, a rarely enforced 1936 antitrust law meant to prevent discriminatory pricing that harms competition.The suit accuses Pepsi of providing payments and allowances to Walmart that were not extended to other retailers, placing smaller businesses at a competitive disadvantage. Although Walmart is named in the allegations, it is not a defendant in the case. The plaintiff argues that Pepsi's pricing tactics unfairly burden other merchants who must pay more for the same products.This legal action echoes a previous Federal Trade Commission (FTC) lawsuit filed against Pepsi in January under the Biden administration. However, the second Trump administration dropped the case in May, with Trump-appointed FTC Chair Andrew Ferguson criticizing it as a politically motivated effort launched too late in the prior administration's term. The FTC has not commented on the new private lawsuit.The class action seeks unspecified damages on behalf of thousands of Pepsi purchasers nationwide. Neither Pepsi nor Walmart has publicly responded to the allegations.Pepsi accused of price discrimination in new merchant class action | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Martin Brenner, iBio

Careers in Discovery

Play Episode Listen Later Aug 6, 2025 55:22

This week on Careers in Discovery, we're joined by Martin Brenner, CEO and CSO of iBio and one of Biotech's most experienced R&D leaders. Martin shares his journey from pharmacologist to global R&D executive, with leadership roles at Pfenex, Recursion, AstraZeneca, and Stoke Therapeutics. Now at iBio, he leads a company developing gene therapies for rare diseases - while applying lessons from decades of drug development to a new generation of science. We talk about the power of simplicity in communication, why leaders need to create space for science to breathe, and how to build R&D teams that are lean, smart, and focused on what matters most.

365. Rethinking income: dividend growth and share buybacks

FundCalibre - Investing on the go

Play Episode Listen Later Aug 6, 2025 28:18

Sue Norfolk, manager of the Schroder Income Growth Trust, shares how UK companies are adapting their capital distribution strategies with a shift towards share buybacks and stable dividend growth. We also cover the evolving landscape of domestic versus international opportunities, sector-specific insights into financials, consumer discretionary, and industrials, and how geopolitical tensions are factored into portfolio decisions. Finally, we examine the fund's bottom-up stock selection approach, recent adjustments in holdings like AstraZeneca, GSK, and Burberry, and the current valuation-driven opportunities in the market.What's covered in this episode:Schroder Income Growth's dividend hero statusDividends, share buybacks or social dividends?How volatility is factored into the portfolioStaying focused on bottom-up stock pickingThe impact of US politics on the trustRight and wrong tariff callsThe attractive nature of UK mid-capsA closer look at financials and customer discretionaryMaking calls on defence and industrialsWhy this manager favours AstraZeneca over GSKDoubling down on BurberryWhy UK equity is still attractive todayMore about the trust: Launched in 1995, the Schroder Income Growth Trust's principal aim is to provide real growth of income in excess of the rate of inflation. It invests mainly in the shares of UK larger and medium-sized companies, although it can also invest some of the portfolio in the shares of firms listed abroad.Learn more on fundcalibre.comPlease remember, we've been discussing individual companies to bring investing to life for you. It's not a recommendation to buy or sell. The fund may or may not still hold these companies at the time of listening. Elite Ratings are based on FundCalibre's research methodology and are the opinion of FundCalibre's research team only.

uk growth income rethinking launched astrazeneca complease dividend burberry gsk buybacks

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Sameh Gaballa, MD - Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 4, 2025 32:48

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/DCA865. CME/NCPD credit will be available until July 30, 2026.Off-the-Shelf and on the Mark in NHL: Strategic Approaches With Bispecific Antibodies and ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

patients strategic approaches disclosure astrazeneca shelf antibodies medical education genentech off the shelf adcs accreditation council pvi sameh continuing medical education accme pharmacy education acpe practice aids peerview institute

Lessons From the Frontlines of Humanitarian Crises: Dr. Joanne Liu, Former International President of Médecins Sans Frontières and Author of Ebola, Bombs and Migrants

Play Episode Listen Later Jul 31, 2025 32:48

“Pandemics are a political choice. We will not be able to prevent every disease outbreak or epidemic but we can prevent an epidemic from becoming a pandemic,” says Dr. Joanne Liu, the former International President of Médecins Sans Frontières/Doctors Without Borders and a professor in the School of Population and Global Health at McGill University. You are in for a lot of that sort of frank and clear-eyed analysis in this episode of Raise the Line from Dr. Liu, whose perspective is rooted in decades of experience providing medical care on the frontlines of major humanitarian and health crises across the globe, as well as wrangling with world leaders to produce more effective responses to those crises and to stop attacks on medical facilities and aid workers in conflict zones. Firsthand accounts from the bedside to the halls of power are captured in her new book Ebola, Bombs and Migrants, which focuses on the most significant issues during her tenure leading MSF from 2013-2019. The book also contains insights about the geopolitical realities that hamper this work, including lax enforcement of international humanitarian law, and a focus on national security that erodes global solidarity. Join host Lindsey Smith as she interviews this leading voice on our preparedness to meet the needs of those impacted by violent conflict, forced migration, natural disasters, disease outbreaks and other grave challenges. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

covid-19 ai interview school technology coronavirus lessons pandemic doctors podcasts viruses testing vaccines raise nurses cdc fda public health psychedelics pfizer epidemics medicare machine learning omicron public policy population moderna lsd medicaid bombs crises johns hopkins university mark cuban astrazeneca big pharma ebola front lines migrants humanitarian health insurance telehealth mdma edtech global health healthcare system mcgill university psilocybin delta variant primary care pharmaceuticals wearables digital health continuing education liu home care firsthand medical education rare diseases gene editing medicare advantage online education doctors without borders health care reform sans fronti migrant crisis msf chelsea clinton government policy drug development elsevier health professions osmosis value based care flatten the curve nursing school eric topol learning sciences international president flipped classroom nursing education remote monitoring drug costs pharmacy benefit managers decision support johnson & johnson education innovation spaced repetition international humanitarian law centers for disease control vivian lee lindsey smith rare disorders virus outbreak dental education joanne liu hospital systems healthcare entrepreneurs shiv gaglani medical degrees frontline providers

Season 3 - Ep.21: Atrial fibrillation in heart failure - Temperature management following cardiac arrest

Play Episode Listen Later Jul 31, 2025 25:28

This episode covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Season 3 - Ep.21: Extended interview on post resuscitation care

Play Episode Listen Later Jul 31, 2025 8:28

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Pharma and Biotech Daily: New Novo Nordisk CEO, FDA Reversal on Sarepta, and More

MONEY FM 89.3 - Your Money With Michelle Martin

Play Episode Listen Later Jul 30, 2025 0:49

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

ceo news cdc fda astrazeneca pharma reversal biotech merck novo nordisk senate democrats dmd sarepta

Sarepta Gets Reprieve, RFK Jr.'s New Changes, Roche's Alzheimer's Comeback and Q2 Earnings

BioSpace

Play Episode Listen Later Jul 30, 2025 19:17

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug. Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week. Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.” On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year. In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike. And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.

Market View: From Scandals to Snack-Serving Robots — HPL, Envy, and the New Era of Trade

Play Episode Listen Later Jul 30, 2025 25:01

What do F1-linked scandals, Ponzi schemes, and popcorn-serving robot dogs have in common? Hosted by Michelle Martin with Ryan Huang, today’s Market View dives into Hotel Properties Limited (HPL) and its Orchard Road asset play, and the fallout from Envy Asset Management’s billion-dollar nickel scam. We also unpack shifting US trade policy under President Trump and its implications for Singapore, with the 10% tariff still looming. In our corporate roundup, we dissect the latest from AstraZeneca, Merck, Novo Nordisk, UOB’s United Overseas Insurance, and First REIT. Finally, we marvel at Unitree, UBTech Robotics, and Agibot at China’s AI Summit. From legal woes to leaping robot dogs—don’t miss today’s episode.See omnystudio.com/listener for privacy information.

SOTS 2nd Hour: Union Pacific & Norfolk CEOs, AstraZeneca CEO, & Consumer Stock Picks 7/29/25

Squawk on the Street

Play Episode Listen Later Jul 29, 2025 42:40

A huge morning of earnings and deal news: Carl Quintanilla, Sara Eisen, and David Faber kicked off the hour with better-than-expected consumer data – along with a First On CNBC interview with the CEOs of Union Pacific and Norfolk Southern as they sign a new deal for the largest buyout EVER in the industry – and become the first coast-to-coast freight operator in the US… On the earnings front: hear from one analyst who calls Boeing a buy on new numbers there, more on how to navigate consumer-facing stocks after a slew of mixed reports out of travel and retail, and what's ahead for pharma on the tariffs front according to the CEO of AstraZeneca, as shares gain following strong results… Plus: what's driving Novo Nordisk shares to their worst day since 1987. Squawk on the Street Disclaimer

ceo ceos consumer boeing astrazeneca norfolk novo nordisk norfolk southern union pacific stock picks squawk sots david faber carl quintanilla us on

AstraZeneca CEO Talks Drug Sales in US

Bloomberg Talks

Play Episode Listen Later Jul 29, 2025 14:29 Transcription Available

AstraZeneca may sell some of its medicines directly to patients in the US, according to Chief Executive Officer Pascal Soriot. AstraZeneca is looking to the US for growth, with Soriot saying the company will be self-sufficient in the US in a couple of months. He speaks with Bloomberg's Carol Massar, Tim Stenovec, and Madison MullerSee omnystudio.com/listener for privacy information.

sales drug bloomberg astrazeneca carol massar tim stenovec

Regnskab fra svensk medicinalgigant og fokus på energi

Millionærklubben

Play Episode Listen Later Jul 29, 2025 60:58

Der er fuld drøn på nyhedsstrømmen fra finanssektoren, hvor tirsdag bl.a. byder på friske regnskabstal fra den svensk-britiske medicinalgigant, AstraZeneca. Millionærklubben ser på tallene sammen med adm. direktør i investeringsfonden Global Health Invest, Claus Johansen. Nyt er der også på energifronten med den netop indgåede rammeaftale for handel og investeringer mellem Europa og USA. Hvad det får af betydning for råvaremarkederne, spørger vi chefanalytiker hos Global Risk Management, Arne Lohmann Rasmussen, om. Med i studiet er chefanalytiker Lau Svenssen fra Svenssen & Tudborg, der tjekker ind på dagens aktuelle marked og samler op på gårsdagens relativt upopulære udmelding fra Bavarian Nordic.Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

united states europa fokus med nyt astrazeneca hvad energi svensk bavarian nordic global risk management

Europe Market Open: Lacklustre trade as the week's risk events kick off

Ransquawk Rundown, Daily Podcast

Play Episode Listen Later Jul 29, 2025 4:24

APAC stocks traded with a mostly negative bias after a similar performance among global peers.European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 0.2% after the cash market closed with gains of 0.3%.FX markets are contained, EUR/USD sits on a 1.15 handle, USD/JPY maintains its footing above the 148 mark.Bund futures lacked direction overnight. Crude futures were little changed but held on to most of the prior day's spoils.Looking ahead, highlights include Spanish GDP Estimate, US Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from UK, Germany & US.Earnings from AstraZeneca, Barclays, Unite, L'Oreal, Air Liquide, Orange, Kering, Banca Generali, Terna, Endesa, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Pharma and Biotech Daily: The Latest in Industry Partnerships, Drug Developments, and Regulatory Updates

The Oncology Nursing Podcast

Play Episode Listen Later Jul 29, 2025 1:48

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.

Business Of Biotech

Play Episode Listen Later Jul 28, 2025 54:07 Transcription Available

We love to hear from our listeners. Send us a message. On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

ceo business fusion frontier astrazeneca innovating biotech sanofi ebrahim curium

Building psychological safety in nonprofit organizations with Michael Randel

Mission Impact

Play Episode Listen Later Jul 28, 2025 50:00

In episode 128 of Nonprofit Mission: Impact, Michael Randel joins Carol to explore how psychological safety—often dismissed as a “soft” concept—plays a critical role in nonprofit team performance, learning, and innovation. They discuss: The connection between organizational readiness and the deeper human dynamics that shape effective leadership and collaboration. What psychological safety looks like in action, Why it's vital in today's polarized climate, How nonprofit leaders can foster inclusive, high-trust environments where people feel safe to speak up, take risks, and learn from mistakes. Episode highlights: [00:08:55]

185 Non-traditional Pharmacy Careers: What It's Like to Be a Clinical Development Scientist in Pharma

Pharmacist Diaries

Play Episode Listen Later Jul 28, 2025 54:43

*This podcast episode was originally a YouTube LIVE with Q&A which you can watch on my YouTube channel here. This is a series of episodes I am doing on non-traditional careers running from July to December 2025. Sign up to my shared Google Calendar here so you never miss an episode*In this episode of Pharmacist Diaries, I'm joined by Adam Quicaro, a pharmacist who transitioned into the world of clinical development at Alexion Pharmaceuticals, the rare disease arm of AstraZeneca. This conversation kicks off our brand-new series exploring non-traditional pharmacy careers — and Adam's story is the perfect place to start.Adam walks us through his journey from working in an independent community pharmacy during high school to landing a fellowship in medical affairs, and eventually finding his true calling in clinical development. He shares how his childhood curiosity and love for science led him to pharmacy, but how it was a blend of strategic thinking, innovation, and a desire to solve complex problems that pulled him toward the pharmaceutical industry.We explore the differences between medical affairs and clinical development, what a typical day looks like in his role, and why pharmacists are uniquely positioned to succeed in the pharma space — especially those with a strong foundation in therapeutics, pharmacology, and patient care.Adam also opens up about the realities of salary expectations, comparing entry-level roles and fellowships, and highlighting the long-term rewards of working in industry. He talks about the benefits of hybrid working, generous leave policies, and how this role supports him not just as a pharmacist, but as a new dad seeking balance and fulfillment.If you've ever wondered what it's like to work behind the scenes of a clinical trial, or if you're curious about how to pivot out of a traditional role, this episode is full of honest, practical advice and inspiration. Whether you're a student or seasoned pharmacist, Adam's story will get you thinking about what's possible.JOIN MY NEWSLETTER COMMUNITY:This isn't your typical pharmacy newsletter - it's a weekly mentoring session delivered straight to your inbox, packed with actionable insights for ambitious pharmacy students. Each week, I share:Building multiple income streams while maintaining clinical practiceTime management secrets and productivity hacks I swear by ⚡Systems and strategies that keep it all running smoothly ⚙️Personal reflections on growth, failure, and resilienceBehind-the-scenes looks at podcast production and brand buildingIf you are ready to think differently about your future in pharmacy, sign up

amazon personal building partnership scientists careers pharmacy i love astrazeneca nontraditional google calendar clinical development alexion pharmaceuticals jamie wilkey

Episode 373: Biomarker Testing in Prostate Cancer

Play Episode Listen Later Jul 25, 2025 16:10

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing. This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Pope & Schapiro: AstraZeneca, a campaign shakeup, and possible election changes

Virginia Public Radio

Play Episode Listen Later Jul 25, 2025

Change has been a theme in political news over the past few days. Politics analyst Jeff Schapiro and Michael Pope recap the week in politics and state government.

politics change elections campaign pope shakeup astrazeneca schapiro michael pope

Pharma and Biotech Update: Roche drops obesity asset, Novartis strikes deal, AstraZeneca's Phase III win, and more!

Play Episode Listen Later Jul 25, 2025 0:56

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

news opportunities fda drops strikes asset obesity astrazeneca pharma biotech roche novartis eli lilly gsk genentech phase iii csl sarepta

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

CCO Oncology Podcast

Play Episode Listen Later Jul 25, 2025 35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBCSERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancerINAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancerPresenters:Kevin Kalinsky, MD, MS, FASCOProfessor of MedicineLouisa and Rand Glenn Family Chair in Breast Cancer ResearchWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaSara M. Tolaney, MD, MPHChief, Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.Link to full program: https://bit.ly/4lFS4BC

ai ms md independent studies breast cancer mph astrazeneca annual meetings cme asco her2 gilead sciences pd l1 thp asco annual meeting daiichi sankyo pbo ctdna cdk4 fasco conference coverage pik3ca esr1 sara m tolaney kevin kalinsky

Rare Disease Parents Create a New Model for Drug Development: Nicole Johnson, Co-Founder and Executive Director of FOXG1 Research Foundation

vote richmond committee delays rental astrazeneca inspection

Play Episode Listen Later Jul 24, 2025 28:56

“As parents dedicated to getting a treatment for our children in their lifetimes, we have turned the rare disease drug development landscape upside down and created a new model,” says Nicole Johnson, co-founder and executive director of the FOXG1 Research Foundation. That's not an exaggeration, as the foundation is on track to make history as it begins patient clinical trials on a gene replacement therapy next year. The former TV news producer and media executive unexpectedly entered the world of patient advocacy and drug research after her daughter, Josie, was born with FOXG1, a genetic disorder which causes severe seizures and impedes normal movement, speech, and sleep among other problems. Johnson is also making an impact in another important dimension of the rare disease space in her efforts to educate parents, teachers, and students about disability inclusion through her Joyfully Josie book series and “Live Joyfully” education programs. Tune-in to this fascinating Year of the Zebra conversation with host Lindsey Smith to find out how the foundation is aiming to bring a drug to market in less than half the time and at a fraction of the cost than the industry standard, and how this model might impact research on other rare disorders. Mentioned in this episode:FOXG1 Research FoundationJoyfully Josie Book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

covid-19 tv ai interview technology coronavirus pandemic doctors podcasts parents co founders executive director viruses executives testing vaccines nurses cdc fda public health psychedelics pfizer epidemics medicare machine learning omicron public policy moderna lsd medicaid johns hopkins university mark cuban astrazeneca big pharma health insurance telehealth mdma edtech healthcare system zebra psilocybin delta variant primary care pharmaceuticals wearables digital health continuing education home care medical education rare diseases gene editing medicare advantage new model online education health care reform chelsea clinton government policy drug development elsevier health professions osmosis value based care flatten the curve nursing school disability inclusion research foundation eric topol learning sciences nicole johnson flipped classroom nursing education remote monitoring drug costs pharmacy benefit managers decision support johnson & johnson education innovation spaced repetition centers for disease control vivian lee rare disorders lindsey smith virus outbreak dental education hospital systems foxg1 shiv gaglani healthcare entrepreneurs medical degrees frontline providers

7/24/25 - Richmond committee delays vote on rental inspection program

VPM Daily Newscast

Play Episode Listen Later Jul 24, 2025 7:04

Virginia sees "alarming" rise in child drownings; Maymont celebrates 100 years; AstraZeneca announces new facility.

Pharma and Biotech Daily: FDA Voucher Program, Sarepta's Elevidys Halts, and AstraZeneca's $50 Billion Investment

news research fda cart astrazeneca pharma biotech roche glp gene therapy halts voucher drug prices neurodegenerative diseases sarepta billion investment sirna

Play Episode Listen Later Jul 24, 2025 1:17

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has initiated a voucher program to address lower drug prices and boost domestic investment, with up to five companies being selected based on national priorities. Roche has halted shipments of Sarepta's Elevidys gene therapy after reports of patient deaths. Sarepta is under FDA scrutiny following a third patient death, while the agency welcomes a new top drug regulator and rejects multiple new drugs from entering the market. Insights from women in biopharma highlight the importance of resilience. Zhen Li, an engineer, is playing a crucial role in shaping the field of siRNA. Research suggests that GLP-1s may offer protection against neurodegenerative diseases. Dispatch Bio enters the scene with a substantial $216 million investment for universal CAR T therapy. Sarepta complies with an FDA request to suspend US shipments of Elevidys, raising concerns about transparency and impacting the company's reputation. Replimune experiences a significant drop in stock value following an FDA rejection, while AstraZeneca makes a bold $50 billion investment in US manufacturing to prepare for potential tariffs. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the industry.

Pharma and Biotech Daily: The Latest News and Trends in the Industry

news fda astrazeneca pharma biotech latest news sanofi biogen sarepta therapeutics

Play Episode Listen Later Jul 23, 2025 0:50

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics has halted the distribution of Elevidys in the US after the FDA request, following two deaths. The company's transparency has been called into question, affecting its stock value. Replimmune also faced setbacks after the FDA rejected its melanoma treatment, causing a significant drop in shares. On a more positive note, AstraZeneca has pledged $50 billion for US manufacturing, focusing on drugs like Baxdrostat and oral glp-1 therapies. Sanofi has made a $1.6 billion vaccine acquisition, while Biogen commits $2 billion to expand US drug production. The pharmaceutical industry is seeing various developments and challenges, with companies adapting to regulatory demands and market pressures.

Drugmaker AstraZeneca invests big in the U.S.

Marketplace All-in-One

Play Episode Listen Later Jul 22, 2025 6:55

From the BBC World Service: Drugmaker AstraZeneca says it'll invest $50 billion in the United States by 2030, its biggest-ever manufacturing investment in the country. The AngloSwedish firm plans to build a major new site in Virginia, the latest in a string of big pharma bets on the U.S. as President Donald Trump threatens steep tariffs on drug imports. Plus, a bike shop boss reflects on business during the Tour de France.

united states donald trump astrazeneca tour de france invests drugmaker

Drugmaker AstraZeneca invests big in the U.S.

Marketplace Morning Report

Play Episode Listen Later Jul 22, 2025 6:55

From the BBC World Service: Drugmaker AstraZeneca says it'll invest $50 billion in the United States by 2030, its biggest-ever manufacturing investment in the country. The AngloSwedish firm plans to build a major new site in Virginia, the latest in a string of big pharma bets on the U.S. as President Donald Trump threatens steep tariffs on drug imports. Plus, a bike shop boss reflects on business during the Tour de France.

united states donald trump astrazeneca tour de france invests drugmaker

SoftBank and OpenAI's Joint AI Venture Loses Steam

WSJ Minute Briefing

Play Episode Listen Later Jul 22, 2025 3:10

Plus: China confirms it will hold a top-level summit with the European Union in Beijing this week. And, AstraZeneca plans to invest $50 billion in the U.S. by 2030. Kate Bullivant hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

china news european union wall street journal steam beijing loses joint openai venture astrazeneca softbank

AstraZeneca announces $50 billion investment in the United States

World Business Report

Play Episode Listen Later Jul 22, 2025 26:10

The pharmaceutical giant Astra Zeneca has announced it's to invest $50bn in the US by 2030 as President Trump threatens the sector with tariffs.At a collapsed gold mine in the Democratic Republic of Congo people are using their hands and basic tools to try to reach victims who are trapped underground. And Andrew Peach looks at the rise of ride hailing apps in Thailand and the impact it's having on taxis and Tuk-Tuks.You can contact us on WhatsApp or send us a voicenote: +44 330 678 3033.

united states donald trump thailand whatsapp congo astrazeneca democratic republic billion investment

White House keeps up pressure on Powell

Squawk Box Europe Express

Play Episode Listen Later Jul 22, 2025 26:48

The White House maintains pressure on Federal Reserve Chairman Jerome Powell to cut interest rates but markets appear sanguine. The S&P 500 closes at a fresh record high while Treasury Secretary Scott Bessent tells our colleagues Stateside that he intends to investigate the Fed's decision-making. Brussels is reportedly preparing a range of ‘nuclear options' should the EU fail to agree a trade deal with Washington ahead of President Trump's August 1st deadline. Anglo-Swedish drug firm AstraZeneca says it will invest around $50bn for manufacturing and R&D in the US over the next five years as it braces for potential pharma tariffs.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Prof. Dr. med. Barbara Eichhorst - The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 21, 2025 79:36

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH information, and to apply for credit, please visit us at PeerView.com/JWX865. CME/EBAH credit will be available until July 22, 2026.The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisions With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

therapy patients prof treatments limited second coming disclosure astrazeneca informed medical education newer finite combinations accreditation council treatment decisions pvi continuing medical education accme pharmacy education acpe btki practice aids peerview institute

Pier Luigi Zinzani, MD, PhD - Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 21, 2025 77:18

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

strategy patients integrating luigi disclosure astrazeneca upgrades populations upfront cme md phd medical education first line accreditation council mantle cell lymphoma pvi continuing medical education accme pharmacy education acpe btki practice aids peerview institute

Samuel Cytryn, MD, Yelena Y. Janjigian, MD* - Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 21, 2025 47:49

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUA865. CME/MOC/AAPA/IPCE credit will be available until July 16, 2026.Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

patients disease guidance platforms disclosure astrazeneca medical education cancer care immunotherapy multidisciplinary gastric accreditation council achieving excellence pvi resectable continuing medical education accme pharmacy education acpe practice aids peerview institute yelena y janjigian cme moc aapa ipce

Samuel Cytryn, MD, Yelena Y. Janjigian, MD* - Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 21, 2025 47:49

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUA865. CME/MOC/AAPA/IPCE credit will be available until July 16, 2026.Achieving Excellence in Gastric/GEJ Cancer Care: Multidisciplinary Guidance on Immunotherapy Platforms in Resectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

patients disease guidance platforms disclosure astrazeneca medical education cancer care immunotherapy multidisciplinary gastric accreditation council achieving excellence pvi resectable continuing medical education accme pharmacy education acpe practice aids peerview institute yelena y janjigian cme moc aapa ipce

A Colorful and Comprehensive Option for Visual Learners: Jennifer Zahourek, RN, Founder and CEO of RekMed